SCHEMBL4184412

SCHEMBL4184412

COc1ccc(S(=O)(=O)N[C@@H](C)C(N)=O)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
MEN1 O00255 3/20 0.58
POLB P06746 1/20 0.56
TSHR P16473 1/20 0.56
MAPK1 P28482 1/20 0.56
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CA12 O43570 1/20 0.51
CA9 Q16790 1/20 0.51
FFAR4 Q5NUL3 1/20 0.50
PDE4A P27815 1/20 0.49
PDE4B Q07343 1/20 0.49
PDE4C Q08493 1/20 0.49
PDE4D Q08499 1/20 0.49
KEAP1 Q14145 1/20 0.49
NFE2L2 Q16236 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184408 1.00 KMT2A (0.58) KMT2AMEN1POLBTSHRMAPK1
SCHEMBL8619578 0.89 KMT2A (0.48) KMT2AMEN1ALDH1A1
SCHEMBL24040870 0.83 ALDH1A1 (0.74) KMT2APOLBTSHRMAPK1LMNA
SCHEMBL4180372 0.83 KMT2A (0.61) KMT2AMEN1POLBTSHRMAPK1
SCHEMBL21545401 0.79 RXFP1 (0.49) KMT2AMEN1POLBTSHRMAPK1
SCHEMBL21545399 0.79 RXFP1 (0.49) KMT2AMEN1POLBTSHRMAPK1
SCHEMBL21545606 0.79 RXFP1 (0.49) KMT2AMEN1POLBTSHRMAPK1
SCHEMBL7441253 0.78 KMT2A (0.56) KMT2AMEN1POLBTSHRMAPK1
SCHEMBL21947473 0.78 NPC1 (0.54) KMT2AMEN1POLBTSHRLMNA
SCHEMBL4187133 0.77 KMT2A (0.52) KMT2AMEN1POLBTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 EP disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A KMT2A 3729/4885MEN1 2095/4885POLB 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.